Blog

Drug temporarily reverses autism-like brain changes in adult mice within hours

Mouse research points to autism targets: Rapamycin temporarily reversed autism-like brain changes and improved behavioral symptoms of adult mice exposed to maternal inflammation, researchers reported in Nature Communications. The drug improved brain signaling within hours, although the effects were short-lived, pointing to potential new therapeutic targets for autism.

FDA finalizes three guidances to broaden cancer clinical trial eligibility

The US Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) has finalized a trio of guidance documents to promote greater participation and diversity in oncology clinical trials. The documents address three areas: a patient’s performance status, laboratory values, and washout periods.

Brain implant enables paralyzed man to regain movement

A brain-computer interface that bypasses a spinal cord injury allowed a man with paralysis to move his arms and hands, regain some sense of touch, and perform tasks such as feeding himself after months of training. Some improvements persisted even when the device was turned off, suggesting the therapy may promote lasting nervous system recovery.

Why animal models still matter in drug development:  Patient advocates warn that political momentum to reduce animal testing is outpacing the scientific validation of alternative methods.

Patient advocates urge caution on reducing animal research: A patient advocacy group is urging regulators to validate alternative research methods alongside animal models rather than replacing them prematurely, arguing that current non-animal approaches cannot yet replicate the complexity of whole-body responses. The group warned that moving away from animal research too quickly could leave important safety gaps for vulnerable populations, including pregnant women, children, and people with rare diseases.

European Commission (EC) expands list of well-established technologies under EU MDR (European Union Medical Device Regulation)

The European Commission has published two delegated acts that expand the list of well-established technologies (WET) under the Medical Devices Regulation (MDR) that are exempt from conducting clinical investigations and technical assessments. The first regulation applies to implantable devices and Class III devices, while the second regulation focuses on Class IIb implantable devices.

Louisiana man functionally cured of sickle cell via gene therapy

Metairie man functionally cured of sickle cell disease through gene therapy: A Metairie man is now the first person in Louisiana to be functionally cured of sickle cell disease through gene therapy. Daniel Cressy, 23, of Metairie, La., has become the first person in the state to be functionally cured of sickle cell disease through gene therapy at Manning Family Children’s Hospital. After two years of treatment, Cressy is pursuing his goal of becoming a commercial pilot. “All the support from the state and supporting governing bodies, I think everyone can soon obtain this treatment … keep going, there is hope for a cure,” Cressy says.

The Women’s Health Problem Actress Halle Berry And Nella Want To Help Solve

Actress Halle Berry invests in startup updating a century-old tool for modern women: Actress and women’s health advocate Halle Berry is investing in a startup called Nella, founded by Fahti Khosrowshahi, to modernize the speculum, which is largely the same tool now as it was a century ago. Nella’s speculum is smaller and less uncomfortable, which may reduce the anxiety and discomfort that lead 72% of women to delay annual pelvic exams. “When I found out that a woman designed this for women, I started to feel instantly that we do have power. We can change our future,” Berry said.

New mRNA Delivery Platform Restores Muscle Function in DMD (Duchenne Muscular Dystrophy) Models

Mice with DMD (Duchenne Muscular Dystrophy) regain muscle function after targeted mRNA treatment: Engineered extracellular vesicles delivered full-length dystrophin mRNA to skeletal muscle of mice with Duchenne Muscular Dystrophy (DMD), restoring dystrophin production and improving muscle strength and function, according to a study in Nature Biomedical Engineering. Safety testing with non-human primates found the treatment was well tolerated, supporting its potential as a non-viral alternative to current gene therapies.